As previously reported, Piper Sandler analyst Matt O’Brien upgraded Sight Sciences (SGHT) to Overweight from Neutral with a price target of $9, up from $5. The firm has become increasingly bullish on the TearCare opportunity – though it would still advise some investor patience near-term as the company works to secure coverage from payors. Further, Piper says the company’s surgical glaucoma business has performed better-than-expected in 2025 year-to-date and it sees brighter days ahead in FY26. While shares meaningfully outperformed in 2025, the firm thinks the risk-reward for Sight still skews positive at these levels.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences upgraded to Overweight from Neutral at Piper Sandler
- Sight Sciences price target raised to $12 from $7 at UBS
- Sight Sciences price target raised to $9.10 from $5.50 at Citi
- Sight Sciences price target raised to $12 from $7 at Lake Street
- Sight Sciences management to meet virtually with Lake Street